Newsroom

Biotechnology

Explore the latest breakthroughs and trends in the Biotechnology sector with our newsroom. From cutting-edge innovations in gene therapy and biopharmaceuticals to advancements in medical research and regulatory updates, we provide essential insights into the scientific developments shaping the future of healthcare and life sciences.


Latest Press Releases

Applied BioSciences Provides Corporate Update and 2019 Business Outlook
BiotechnologyCompany Update

Applied BioSciences Provides Corporate Update and 2019 Business Outlook

July 30, 2019 8:00 AM

Key Management appointments, including Raymond W. Urbanski MD, PhD, former business unit Chief Medical Officer at Pfizer Inc., as Chief Executive Officer provides extensive industry leading expertise, strategic focus and discipline on the execution of corporate initiatives Purposefully built strategic business units focused on leveraging science-driven cannabinoid research to address areas of significant unmet needs and access growing markets...

Read more
Principle Investigator Dr. Jorge Hernando Ulloa Reports New 90 Day VenoValve Data at the Second Annual Society of Vascular and Endovascular Surgery Congress of Central America and the Caribbean
BiotechnologyCompany Update

Principle Investigator Dr. Jorge Hernando Ulloa Reports New 90 Day VenoValve Data at the Second Annual Society of Vascular and Endovascular Surgery Congress of Central America and the Caribbean

July 26, 2019 8:31 AM

Reflux Now at Normal Levels in All Four VenoValve Patients IRVINE, CA / ACCESSWIRE / July 26, 2019 / Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that on Thursday, July 25, 2019, Dr. Jorge Hernando Ulloa, the Principle Investigator for HJLI’s first-in-man VenoValve study in Bogota, Colombia, reported new 90 day VenoValve data at the Second Annual...

Read more
Pressure BioSciences Announces First Close and Customer for its Revolutionary Water-Soluble CBD Manufacturing System, the BaroShear K45
BiotechnologyCompany Update

Pressure BioSciences Announces First Close and Customer for its Revolutionary Water-Soluble CBD Manufacturing System, the BaroShear K45

July 25, 2019 9:36 AM

Company Enters the Multi-Billion Dollar CBD Market with Proprietary Instrument System Designed to Significantly Improve the Processing of CBD Oil into High Quality, Water-Soluble Nanoemulsions SOUTH EASTON, MA / ACCESSWIRE / July 25, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the...

Read more
Pieris Pharmaceuticals To Host Second Quarter 2019 Investor Call And Corporate Update On August 1, 2019
BiotechnologyCompany Update

Pieris Pharmaceuticals To Host Second Quarter 2019 Investor Call And Corporate Update On August 1, 2019

July 25, 2019 8:00 AM

BOSTON, MA / ACCESSWIRE / July 25, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a second quarter 2019 investor call on Thursday, August 1, 2019 at 8:00 AM (EDT) to provide a corporate update. To access the call, participants...

Read more
Edesa Biotech Completes Manufacturing for Upcoming Dermatitis Study
BiotechnologyCompany Update

Edesa Biotech Completes Manufacturing for Upcoming Dermatitis Study

July 25, 2019 7:30 AM

TORONTO, ON / ACCESSWIRE / July 25, 2019 / Edesa Biotech, Inc. (NASDAQ: EDSA), a clinical-stage biopharmaceutical company, reported today that the company has completed the manufacturing of its lead drug candidate EB01, a novel sPLA2 inhibitor that Edesa is developing as a potential treatment for chronic allergic contact dermatitis (ACD). Edesa is currently evaluating investigational centers in the U.S. and expects to proceed with enrolling the...

Read more
Pressure BioSciences Announces Second Major Contract Utilizing its BaroFold Protein Refolding and Disaggregation Biopharma Services
BiotechnologyCompany Update

Pressure BioSciences Announces Second Major Contract Utilizing its BaroFold Protein Refolding and Disaggregation Biopharma Services

July 24, 2019 9:14 AM

Company Expects Significant Services Revenue Increase in 2019 as it Expands its BaroFold Platform into the Estimated $44 Billion Global Bioprocess Technology Market SOUTH EASTON, MA / ACCESSWIRE / July 24, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”), a leader in the development and sale of broadly enabling, high pressure-based instruments, platform technologies and related consumables for the worldwide life...

Read more
AzurRx BioPharma Announces Closing of $5.0 Million Public Offering of Common Stock
BiotechnologyCompany Update

AzurRx BioPharma Announces Closing of $5.0 Million Public Offering of Common Stock

July 22, 2019 8:01 PM

BROOKLYN, NY / ACCESSWIRE / July 22, 2019 / AzurRx BioPharma (NASDAQ: AZRX), (“AzurRx” or the “Company”), today announced the closing and funding of its previously announced underwritten public offering of five million shares of its common stock at a price to the public of $1.00 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, are $5.0 million. H.C....

Read more
NUMAFERM Closes Licensing Agreement with PEPDesign
BiotechnologyPartnerships

NUMAFERM Closes Licensing Agreement with PEPDesign

July 22, 2019 8:30 AM

- Low cost production and superior product purity of the diabetes drug liraglutide with NUMAFERM's unique technology platform - Industry seeks optimized generic drug manufacturing methods after liraglutide patent expiration DÜSSELDORF, GERMANY & PŪRĒ, LATVIA / ACCESSWIRE / July 22, 2019 / The Düsseldorf-based NUMAFERM GmbH has signed a licensing agreement for its unique manufacturing process for peptides with PEPDesign SIA. NUMAFERM's...

Read more
Xenetic Biosciences, Inc. Closes $15.0 Million Underwritten Public Offering and  Completes Acquisition of Innovative CAR T Technology Platform
BiotechnologyCompany Update

Xenetic Biosciences, Inc. Closes $15.0 Million Underwritten Public Offering and Completes Acquisition of Innovative CAR T Technology Platform

July 22, 2019 8:00 AM

Innovative XCART technology platform designed to target personalized, patient-specific tumor neoantigens has the potential to transform CAR T cell therapy XCART expected to initially target B-cell lymphomas and has the potential to address multiple tumor types with an initial global market opportunity in Non-Hodgkin Lymphoma of over $5 billion annually FRAMINGHAM, MA / ACCESSWIRE / July 22, 2019 / Xenetic Biosciences, Inc. (NASDAQ: XBIO)...

Read more
Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa to Present New 90 Day VenoValve Data at the Second Annual Society of Vascular and Endovascular Surgery Congress of Central America and the Caribbean On July 25, 2019
BiotechnologyLawsuits

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa to Present New 90 Day VenoValve Data at the Second Annual Society of Vascular and Endovascular Surgery Congress of Central America and the Caribbean On July 25, 2019

July 19, 2019 8:31 AM

Management to Host VenoValve Webcast and Conference Call on July 25, 2019 at 11:00 am Eastern Time IRVINE, CA / ACCESSWIRE / July 19, 2019 / Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that on Thursday, July 25, 2019, Dr. Jorge Hernando Ulloa, Principal Investigator for HJLI’s first-in-man VenoValve study in Bogota, Colombia, will present new 90...

Read more
Pressure BioSciences' PCT Platform Highlighted at International Conference in China
BiotechnologyCompany UpdateConferences

Pressure BioSciences' PCT Platform Highlighted at International Conference in China

July 18, 2019 9:29 AM

Scientists from the Elite Westlake University Report on the Use of the PCT Platform to Significantly Improve the Preparation of Clinical Laboratory Specimens for Evaluation SOUTH EASTON, MA / ACCESSWIRE / July 18, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and related consumables for the worldwide life sciences and...

Read more
AzurRx BioPharma Announces Pricing of $5.0 Million Public Offering of Common Stock
BiotechnologyCompany Update

AzurRx BioPharma Announces Pricing of $5.0 Million Public Offering of Common Stock

July 17, 2019 11:35 PM

BROOKLYN, NY / ACCESSWIRE / July 17, 2019 / AzurRx BioPharma (NASDAQ: AZRX), (“AzurRx” or the “Company”), today announced the pricing of its previously announced underwritten public offering of five million shares of its common stock at a price to the public of $1.00 per share. AzurRx expects to receive aggregate gross proceeds of $5.0 million from the offering. The offering is expected to close on or about July 22, 2019, subject to customary...

Read more
Xenetic Biosciences, Inc. (Nasdaq: XBIO) Announces Pricing of $15.0 Million Underwritten Public Offering
BiotechnologyCompany Update

Xenetic Biosciences, Inc. (Nasdaq: XBIO) Announces Pricing of $15.0 Million Underwritten Public Offering

July 17, 2019 8:45 AM

FRAMINGHAM, MA / ACCESSWIRE / July 17, 2019 / Xenetic Biosciences, Inc. (NASDAQ: XBIO) (“Xenetic” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced the pricing of an underwritten public offering of 2,300,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof)...

Read more
HemaGenetics Announces Upcoming Annual General & Special Meeting of Shareholders, and Entry Into Arrangement Agreement
BiotechnologyCompany UpdateShareholder Meeting

HemaGenetics Announces Upcoming Annual General & Special Meeting of Shareholders, and Entry Into Arrangement Agreement

July 9, 2019 3:10 PM

VANCOUVER, BC / ACCESSWIRE / July 9, 2019 / HemaGenetics Technologies Corp. (the “Company”) is pleased to announce that it will be holding its annual general & special meeting of its shareholders on August 9, 2019 at 10 a.m. at Suite 300 - 1055 W. Hastings St., Vancouver, BC, Canada, V6E 2E9 (the “Meeting”). Shareholders of record as of July 12, 2019 will be entitled to vote at the Meeting. The purpose of the Meeting will be for shareholders to...

Read more
HemaGenetics Technologies Announces Appointment To Its Board of Directors
BiotechnologyCompany Update

HemaGenetics Technologies Announces Appointment To Its Board of Directors

July 5, 2019 1:50 PM

VANCOUVER, BC / ACCESSWIRE / July 5, 2019 / HemaGenetics Technologies Corp. (the “Company” or “HTC”) is pleased to announce the appointment of Richard Paolone as a director of HTC effective immediately. Bio of appointee Richard Paolone - holds a Juris Doctorate and Bachelor of Arts degree. Mr. Paolone is currently employed at a boutique securities law firm that is focused on corporate finance and M&A in Toronto, Ontario. He has experience in the...

Read more
Dyadic Extends Research and Development Agreement with VTT
BiotechnologyCompany Update

Dyadic Extends Research and Development Agreement with VTT

July 5, 2019 8:30 AM

JUPITER, FLORIDA / ACCESSWIRE / July 5, 2019 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global platform biotechnology company, announced today that it has extended its research and development contract ("Contract") through June 2022 with VTT Technical Research Centre of Finland Ltd. ("VTT"), a world leading synthetic biology research and development organization. Under the terms of this extended multi-year...

Read more
Dyadic Joins Russell Microcap(R) Index
BiotechnologyCompany Update

Dyadic Joins Russell Microcap(R) Index

July 2, 2019 8:40 AM

JUPITER, FL / ACCESSWIRE / July 2, 2019 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate the development, lower production costs and improve the performance of biologic vaccines, drugs and other biologic products, at flexible commercial scales, announced today that the Company was added to the...

Read more
Dyadic Announces Appointment of Ping Rawson to CFO
BiotechnologyCompany UpdateManagement Changes

Dyadic Announces Appointment of Ping Rawson to CFO

June 27, 2019 9:23 AM

JUPITER, FL / ACCESSWIRE / June 27, 2019 / Dyadic International, Inc. ("Dyadic") (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs and other biologic products, at flexible commercial scales, today announced the appointment of Ping Rawson to Chief Financial...

Read more
Pressure BioSciences Enters CBD Market with Launch of Novel Instrument System to Revolutionize Manufacturing of High Quality, Water-Soluble CBD
BiotechnologyCompany Update

Pressure BioSciences Enters CBD Market with Launch of Novel Instrument System to Revolutionize Manufacturing of High Quality, Water-Soluble CBD

June 27, 2019 9:05 AM

Purchase Deposits for the New BaroShear K45 System Will be Accepted Immediately; Company Believes Sales into the CBD Market Could Double Current Revenue by Q2 2020 SOUTH EASTON, MA / ACCESSWIRE / June 27, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences...

Read more
Hancock Jaffe Reports Early Positive Results For CoreoGraft Animal Feasibility Study
BiotechnologyCompany Update

Hancock Jaffe Reports Early Positive Results For CoreoGraft Animal Feasibility Study

June 27, 2019 8:30 AM

No Device Failures in Eight Test Subjects IRVINE, CA / ACCESSWIRE / June 27, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, today provided an update on the status of its CoreoGraft animal feasibility study. There have been no device failures in eight animal test subjects where CoreoGrafts have been implanted as heart bypass grafts, with one group observed...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers • July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie • July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers • July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers • June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers • June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers • June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?